Randomized controlled study of berberine combined with methimazole in the treatment of newly diagnosed Graves' disease

Pilot study of berberine combined with methimazole in the treatment of newly diagnosed Graves' disease

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400091126

Enrollment

Unknown

Registered

2024-10-21

Start date

2024-10-21

Completion date

Unknown

Last updated

2024-10-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Graves' disease

Interventions

Combination therapy group:Berberine hydrochloride tablets 0.5, bid+MMI treatment, recommended starting dose of MMI according to domestic and international guidelines

MMI monotherapy group:MMI treatment, recommended starting dose of MMI according to domestic and international guidelines

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: (1) Newly diagnosed GD patients who have not received previous ATD treatment; (2) Age>18 years old; (3) Informed consent to join this study; (4) Initial tolerance to ATD treatment: white blood cells>3.0G/L, neutrophils>1.5G/L, ALT and AST<120U/L.

Exclusion criteria

Exclusion criteria: (1) Pregnant and lactating women; (2) History of hemolytic anemia or glucose-6-phosphate dehydrogenase (G6PD) deficiency in the past; (3) Have used antibiotics or probiotic products in the past three months.

Design outcomes

Primary

Measure	Time frame
Relief rate of GD;	—

Countries

China

Contacts

Public ContactYun Peng

The Seventh Affiliated Hospital of Sun Yat sen University (Shenzhen)

yunpeng@sysush.com+86 186 7669 7218

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026